Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that
occurs in the setting of insulin resistance and increased adiposity. It has rapidly evolved into …

Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD),
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …

NAFLD is the most prevalent form of liver disease in the USA, affecting an estimated 30% of
the population. The condition is associated with increased mortality related to cardiovascular …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and is
strongly associated with the metabolic syndrome. In the last decade, it has become apparent …

Objective: The development of these guidelines is sponsored by the American Association
of Clinical Endocrinologists (AACE) Board of Directors and American College of …

Patients with obesity have a high prevalence of nonalcoholic fatty liver disease (NAFLD),
representing a spectrum of simple steatosis to nonalcoholic steatohepatitis (NASH), without …